Literature DB >> 27795486

Correlation of Pre- and In-Hospital Systolic Blood Pressure in Acute Heart Failure Patients and the Prognostic Implications - Report From the Tokyo Cardiac Care Unit Network Emergency Medical Service Database.

Yasuyuki Shiraishi1, Shun Kohsaka, Kazumasa Harada, Takamichi Miyamoto, Shuzou Tanimoto, Kiyoshi Iida, Tetsuro Sakai, Tetsuro Miyazaki, Mayuko Yagawa, Kenichi Matsushita, Shuta Furihata, Naoki Sato, Keiichi Fukuda, Takeshi Yamamoto, Ken Nagao, Morimasa Takayama.   

Abstract

BACKGROUND: Systolic blood pressure (SBP) is an important prognostic indicator for patients with acute heart failure (AHF). However, its changes and the effects in the different phases of the acute management process are not well known.Methods and 
Results: The Tokyo CCU Network prospectively collects on-site information about AHF from emergency medical services (EMS) and the emergency room (ER). The association between in-hospital death and SBP at 2 different time points (on-site SBP [measured by EMS] and in-hospital SBP [measured at the ER; ER-SBP]) was analyzed. From 2010 to 2012, a total of 5,669 patients were registered and stratified into groups according to both their on-site SBP and ER-SBP: >160 mmHg; 100-160 mmHg; and <100 mmHg. In-hospital mortality rates increased when both on-site SBP and ER-SBP were low. After multivariate adjustment, both SBPs were inversely associated with in-hospital death. Notably, the risk for patients with ER-SBP of 100-160 mmHg (intermediate risk) differed according to their on-site SBP; those with on-site SBP <100 or 100-160 mmHg were at higher risk (OR, 7.39; 95% CI, 4.00-13.6 and OR, 2.73; 95% CI, 1.83-4.08, respectively [P<0.001 for both]) than patients with on-site SBP >160 mmHg.
CONCLUSIONS: Monitoring changes in SBP assisted risk stratification of AHF patients, particularly patients with intermediate ER-SBP measurements. (Circ J 2016; 80: 2473-2481).

Entities:  

Mesh:

Year:  2016        PMID: 27795486     DOI: 10.1253/circj.CJ-16-0837

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  5 in total

1.  Outcome of hospitalised heart failure in Japan and the United Kingdom stratified by plasma N-terminal pro-B-type natriuretic peptide.

Authors:  Yasuyuki Shiraishi; Toshiyuki Nagai; Shun Kohsaka; Ayumi Goda; Yuji Nagatomo; Atsushi Mizuno; Takashi Kohno; Alan Rigby; Keiichi Fukuda; Tsutomu Yoshikawa; Andrew L Clark; John G F Cleland
Journal:  Clin Res Cardiol       Date:  2018-05-21       Impact factor: 5.460

2.  Delay in seeking treatment before emergent heart failure readmission and its association with clinical phenotype.

Authors:  Makoto Takei; Kazumasa Harada; Yasuyuki Shiraishi; Junya Matsuda; Yoichi Iwasaki; Yoshiya Yamamoto; Kenichi Matsushita; Tetsuro Miyazaki; Takamichi Miyamoto; Kiyosi Iida; Shuzo Tanimoto; Yuji Nagatomo; Toru Hosoda; Shun Kohsaka; Takeshi Yamamoto; Ken Nagao; Morimasa Takayama
Journal:  J Intensive Care       Date:  2020-08-26

3.  In-hospital and long-term mortality for acute heart failure: analysis at the time of admission to the emergency department.

Authors:  Carlo Lombardi; Giulia Peveri; Dario Cani; Federica Latta; Andrea Bonelli; Daniela Tomasoni; Marco Sbolli; Alice Ravera; Valentina Carubelli; Nicola Saccani; Claudia Specchia; Marco Metra
Journal:  ESC Heart Fail       Date:  2020-06-26

4.  Phenomapping in patients experiencing worsening renal function during hospitalization for acute heart failure.

Authors:  Ryuichiro Yagi; Makoto Takei; Shun Kohsaka; Yasuyuki Shiraishi; Nobuhiro Ikemura; Satoshi Shoji; Nozomi Niimi; Satoshi Higuchi; Ayumi Goda; Takashi Kohno; Yuji Nagatomo; Yosuke Nishihata; Yasumori Sujino; Mike Saji; Yukinori Ikegami; Shintaro Nakano; Toshiyuki Takahashi; Keiichi Fukuda; Tsutomu Yoshikawa
Journal:  ESC Heart Fail       Date:  2021-09-20

Review 5.  Time-sensitive approach in the management of acute heart failure.

Authors:  Yasuyuki Shiraishi; Masataka Kawana; Jun Nakata; Naoki Sato; Keiichi Fukuda; Shun Kohsaka
Journal:  ESC Heart Fail       Date:  2020-12-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.